SCHEMBL2866520

SCHEMBL2866520

C=CCOc1cc(OCC=C)c(C(=O)c2ccc(F)cc2)c(C(CC)C(=O)OC)c1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.39
MAPT P10636 2/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
POLB P06746 1/20 0.39
LSS P48449 2/20 0.35
ADRB2 P07550 2/20 0.35
ADRB1 P08588 2/20 0.35
ADRB3 P13945 2/20 0.35
LIG1 P18858 1/20 0.35
ALDH1A1 P00352 2/20 0.34
FLT3 P36888 1/20 0.34
LMNA P02545 1/20 0.34
CHRNA7 P36544 1/20 0.34
PTPN1 P18031 1/20 0.34
KAT6A Q92794 1/20 0.34
LDHA P00338 1/20 0.34
LDHB P07195 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2858288 0.91 FLT3 (0.43) KDM4EMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL6032268 0.91 MAPT (0.49) KDM4EMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL2861148 0.91 KDM4E (0.40) KDM4EMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL2856151 0.89 ADRB2 (0.39) KDM4EMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL2857454 0.89 KDM4E (0.43) KDM4EMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL2871401 0.88 MAPT (0.42) KDM4EMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL2861694 0.86 KDM4E (0.45) KDM4EMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL2857059 0.85 KDM4E (0.44) KDM4EMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL2866300 0.85 KDM4E (0.38) KDM4EMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL2856160 0.84 ADRB2 (0.38) KDM4EMAPTNPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1642880-B1 HSP90 FAMILY PROTEIN INHIBITORS KYOWA HAKKO KIRIN CO LTD (JP) 2013-09-04 EP disclosed
US-7767693-B2 Hsp90 family protein inhibitors KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-08-03 US disclosed
US-20090247522-A1 Hsp90 FAMILY PROTEIN INHIBITORS KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-10-01 US disclosed
US-7538224-B2 Hsp90 family protein inhibitors KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-05-26 US disclosed
US-20070032532-A1 Hsp90 family protein inhibitors KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-02-08 US disclosed
EP-1642880-A1 HSP90 FAMILY PROTEIN INHIBITORS KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-04-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032532-A1 Hsp90 family protein inhibitors HSP90AB1, HSP90B1, HSP90AB2P KDM4E 2968/4885MAPT 1791/4885NPC1 1079/4885
US-20090247522-A1 Hsp90 FAMILY PROTEIN INHIBITORS HSP90AB1, HSP90B1, HSP90AB2P KDM4E 2968/4885MAPT 1791/4885NPC1 1079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.